NSI-566

Drug Name: NSI-566
Company: NeuralStem
Location: US-Maryland
Website: http://www.neuralstem.com
Drug Type: Stem Cell Therapy
Conditions: ALS, spinal cord injury
Mechanism Type: Neuroprotection
Mechanism: NSI-566 are human spinal cord stem cell (HSSCs) that are administered into the gray matter of the spinal cord. In mouse models of ALS, NSI-566 cells expressed neutrophic factors and established synaptic connections with motor neurons. The cells are intended to provide neuroprotection to motor neurons in ALS patients.
U.S. Status for ALS: Phase II

References:
[1] Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Glass, JD. et al. Neurology. 2016 Jul 26;87(4):392-400.
[2] Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Riley, J et al. Neurosurgery. 2014 Jan;74(1):77-87.
[3] Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. Xu, L et al. J Comp Neurol. 2009 Jun 1;514(4):297-309.

Last updated June 21st, 2017

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail